A Study of Patients With HER2-Positive Metastatic Breast Cancer

Genentech

Status: Completed

Conditions: Breast Cancer

Study type: Observational

Funder types: Industry

Identifiers

NCT00105456

H2757n

Details and patient eligibility

About

This is a prospective observational cohort study designed to describe effectiveness and safety (treatment outcomes and clinically significant cardiac adverse events, respectively) in patients with HER2-positive metastatic breast cancer.

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Signed Informed Consent document (unless the IRB has granted a waiver of consent)
• Signed Authorization for the Use and Disclosure of Health Information document
• HER2-positive breast cancer
• Initial diagnosis of metastatic (Stage IV) breast cancer within 6 months prior to enrollment
• Availability of cancer-specific historical data points in the patient's medical records

Exclusion criteria

• There are no exclusion criteria for participation in this trial